Efficacy and Safety of Tongren-Dahuoluo Bolus in Patients with Knee Osteoarthritis

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Status and phase

Not yet enrolling

Phase 4

Conditions

Knee Osteoarthritis (Knee OA)

Treatments

Drug: Tongren-Dahuoluo Bolus

Drug: Tongren-Dahuoluo Bolus Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT06674759

2023-170-YW-01

Details and patient eligibility

About

The clinical trial has a research cycle of 24 weeks. The first 12 weeks are multicenter, randomized, double-blind, controlled trials. A total of 72 patients with knee osteoarthritis with liver-kidney deficiency syndrome and/or cold-dampness arthralgia syndrome are planned to be enrolled and randomly assigned to the control group (Tongren-Dahuoluo Bolus) and the treatment group (Tongren-Dahuoluo Bolus Placebo) in a 1:1 ratio. The purpose is to compare the safety and efficacy of Tongren-Dahuoluo Bolus and placebo in treating knee osteoarthritis. A long-term blind extension study will be conducted in the next 12 weeks. All subjects will take Tongren-Dahuoluo Bolus orally to evaluate the long-term safety, tolerability, and efficacy of Tongren-Dahuoluo Pills in treating patients with knee osteoarthritis.

Enrollment

72 estimated patients

Sex

All

Ages

40 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female, aged 40 to 75 years old;
Meet the diagnostic criteria for primary knee osteoarthritis (KOA) (the diagnostic criteria refer to the 1995 American College of Rheumatology classification criteria for knee osteoarthritis);
Meet the diagnostic criteria for liver and kidney deficiency and (or) cold and dampness obstruction in the group standard of the Chinese Association of Traditional Chinese Medicine "Guidelines for Combination of Osteoarthritis Symptoms";
X-ray examination of the joints is graded as I to III (knee joint Kellgren/Lawrence e scoring standard);
Knee pain score ≥40mm in the past week (assessed by VAS standard);

Exclusion criteria

Patients with other rheumatic diseases such as Sjögren's syndrome, gout, rheumatoid arthritis, or a history of human immunodeficiency virus (HIV);
Patients with severe lesions of important organs such as the heart, liver, and kidney, abnormal liver function (alanine or aspartate aminotransferase or glutamine transpeptidase>1.5 times the upper limit of normal value); or abnormal renal function (serum creatinine level> upper limit of normal value); white blood cell (white blood cell, WBC) or platelet (platelet, PLT) below the lower limit of normal value; or diabetic patients with poor blood sugar control in the recent period (glycosylated hemoglobin>8.0%);
Patients with suppurative, nonspecific, and other infectious knee arthritis;
Patients with traumatic, villonodular pigmentation and other lesions with knee synovium as the main lesions;
Patients with advanced joint deformity or disability; A randomized controlled study on Tongren Dahuoluowan in the treatment of knee osteoarthritis Version number: 2023009P8A01 Version date: December 23, 2022
Allergic constitution and allergic to the test drug;
Pregnant, pregnant, or lactating women;
Those who are taking antidepressants, anticonvulsants, opioids, sedatives and glucocorticoids;
Patients who have received intra-articular treatment with sodium hyaluronate within 4 weeks before screening; those who have taken drugs containing chondroitin sulfate/glucosamine/diacerein within 3 months before screening; those who have used biological agents within 3 months before screening;
Patients with organ failure symptoms;
Those who have participated in any other drug trials within 1 month before selection;
Those who the researcher believes are not eligible to join this clinical trial